Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 301–400 of 2,039
Orandi, B. J., Chen, Y., Li, Y., Charyton, D., Lentine, K. L., Lee, B. P., Ali, N., DeMarco, M. P., Weintraub, M. A., Bae, S., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000750 · Cited by 38
Wei, L., Mo, W., Lan, S., Yang, H., Huang, Z., Liang, X., Li, L., Xian, J., Xie, X., Qin, Y., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1861940 · Cited by 48
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 40
Vuppalanchi, R., Loomba, R. S., Sanyal, A. J., Nikooie, A., Tang, Y., Robins, D. A., Brouwers, B., & Hartman, M. L. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18042 · Cited by 38
Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez‐Valderas, E., Allen, S. E., Ranta, K., Torcello‐Gómez, A., & Thieu, V. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14943 · Cited by 36
“The study design of all five SURPASS trials is summarized in Figure S1 and has previously been published.(6-10) All tirzepatide doses in the SURPASS trials were initiated at 2.”
BackgroundMethodResultInfluentialArredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae319 · Cited by 35
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Kreiner, F. F., Schytz, P. A., Heerspink, H. J. L., von Scholten, B. J., & Idorn, T. (2023) · Biomedicines · doi:10.3390/biomedicines11092498 · Cited by 52
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis
Guo, X., Asthana, P., Zhai, L., Cheng, K. W., Gurung, S., Huang, J., Wu, J., Zhang, Y., Mahato, A. K., Saarma, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45452-3 · Cited by 47
“…listed in association with current therapies are not critical issues for tirzepatide, semaglutide, and orforglipron, clinical trials have revealed that a quarter of participants taking one of these drugs reported that they discontinued the treatments due to gastrointestinal adverse events 8,9 .”
BackgroundFrom metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Roy, A., Dawson, V. L., & Dawson, T. M. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00712 · Cited by 47
Hannon, T. S., Chao, L. C., Pérez, M. B., Pamidipati, K. C., Landó, L. F., Lee, C. J., Patel, H., & Bergman, B. K. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01774-x · Cited by 65
Self-citationThe Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Jung, H. N., & Jung, C. H. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22012 · Cited by 42
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Patoulias, D., Popovic, D. S., Stoian, A. P., Janež, A., Sahebkar, A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108529 · Cited by 40
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
“The dual-acting GLP-1 and GIP receptor agonist tirzepatide has been reported to be more effective for weight reduction than classical GLP-1R agonists [42,43].”
BackgroundSamuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70004 · Cited by 35
Zhu, D., Wang, W., Tong, G., Ma, G., Ma, J., Han, J., Zhang, X., Liu, Y., Gan, S., Qin, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52353-y · Cited by 34
“…T2DM and obesity are needed to compare ecnoglutide-induced weight loss to other GLP-1 analogs, which included − 2.05 to − 2.45kg for liraglutide (1.2 and 1.8 mg) at 52 weeks 7 , − 3.73 to − 4.53kg for semaglutide (0.5 to 1.0mg) at 30 weeks 8 , and − 5.7kg for semaglutide (1.0mg) at 40 weeks 9 .”
Influentialle Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36
“pants with T2D, all doses of tirzepatide (5, 10, 15 mg) resulted in greater reductions in body weight and HbA1c than semaglutide 1 mg.(29) Similarly, an ITC leveraging data from the SURPASS-2 and SUSTAIN FORTE trials showed that tirzepatide 10 and 15 mg resulted in significantly greater reductions in body weight and H…”
MethodDoggrell, S. A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2206560 · Cited by 34
“been introduced for the treatment of diabetes and shown to have greater benefits than semaglutide alone [6], and this may be due to the additional stimulation of GIP receptors with tirzepatide, compared to just stimulating GLP-1 receptors”
BackgroundKaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 58
Lipidization as a tool toward peptide therapeutics
Myšková, A., Sýkora, D., Kuneš, J., & Maletínská, L. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2284685 · Cited by 41
Novel mechanisms involved in leptin sensitization in obesity
Pena-León, V., Pérez-Lois, R., Villalón, M. C., Prida, E., Muñoz-Moreno, D., Fernø, J., Quiñones, M., Al–Massadi, O., & Seoane, L. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116129 · Cited by 46
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M. (2024) · Diseases · doi:10.3390/diseases12090204 · Cited by 34
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 46
The promise of tirzepatide: A narrative review of metabolic benefits
Sokary, S., & Bawadi, H. A. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.03.008 · Cited by 44
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Kokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 34
Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Mechanisms of bariatric surgery for weight loss and diabetes remission
Yin, M., Wang, Y., Han, M., Liang, R., Li, S., Wang, G., & Gang, X. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13443 · Cited by 46
“64 Interestingly, the superior efficacy of GIPR-GLP-1R coagonist tirzepatide 65 in T2D has drawn attention to the role of GIP in metabolism in recent years.”
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Polypharmacology: new drugs in 2023–2024
Ryszkiewicz, P., Malinowska, B., & Schlicker, E. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00715-8 · Cited by 45
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“%) with the 15 mg dose [9].”
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 57
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 42
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 44
Tang, Y., Zhang, L., Zeng, Y., Wang, X., & Zhang, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016639 · Cited by 38
“Three different levels of tirzepatide (5 mg, 10 mg, and 15 mg) were used in five studies (Del Prato et al., 2021; Frias et al., 2021; Ludvik et al., 2021; Rosenstock et al., 2021; Dahl et al., 2022).”
BackgroundMethodResultInfluentialNauck, M. A., Mirna, A. E. A., & Quast, D. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14988 · Cited by 32
“Our meta-analysis confirms the general superiority over basal insulin treatment of IBGLMs in controlling body weight (Figure S4), the lack of a clinically relevant general difference between short- and long-acting GLP-1RAs,(1,2) the more effective lowering of body weight with semaglutide as compared with other GLP-1RA…”
ResultGlucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31
Meng, Z., Yang, M., Wen, H., Zhou, S., Chuan, X., & Wang, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1121387 · Cited by 38
“The heterogeneity is mainly from Frias (2021), in which the participants were encouraged to change injection sites constantly, whereas the other studies did not mention this method.”
BackgroundYates, T., Biddle, G. J. H., Henson, J., Edwardson, C. L., Arsenyadis, F., Goff, L. M., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15400 · Cited by 31
Self-citationGogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
Self-citationWang, W., Davis, P. B., Qi, X., Gurney, M. E., Perry, G. L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351329 · Cited by 38
“43,60 GIP receptors are expressed in many regions of the brain.”
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
“Its anti-inflammatory effects, including reduced hs-CRP and IL-6 levels, further contribute to cardiovascular protection [14].”
InfluentialUrva, S., Quinlan, T., Landry, J., Ma, X., Martin, J. A., & Benson, C. T. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01140-3 · Cited by 31
The cardiovascular effects of novel weight loss therapies
Usman, M., Davies, M. J., Hall, M. E., Verma, S., Anker, S. D., Rosenstock, J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad664 · Cited by 31
Self-citationFrias, J. P., De Block, C., Brown, K., Wang, H., Thomas, M. K., Zeytinoglu, M., & Maldonado, J. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae038 · Cited by 40
Self-citationDing, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31
Ros-Madrid, I., Cano-Mármol, R. P., Ferrer-Gomez, M., & Ramos-Molina, B. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0148 · Cited by 31
Kiyosue, A., Dunn, J. P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., & Heine, R. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14952 · Cited by 30
“SURPASS-2 did not enrol participants in any East Asian country, so data from this trial were not included.(24) All trials were multicentre, randomized, parallel group phase 3 trials that compared the efficacy and safety of once-weekly tirzepatide 5, 10 and 15 mg versus placebo or active comparator in adults with type…”
Self-citationMechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 34
Jensen, T. L., Brønden, A., Karstoft, K., Sonne, D. P., & Christensen, M. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s419304 · Cited by 36
“13,29,33,48,49 Semaglutide in doses approved for weight management (2.4 mg semaglutide once weekly) resulted in a weight loss of 6.2% relative to placebo (treatment policy estimand) in individuals with T2D after 68 weeks in the STEP-2 trial.”
BackgroundInfluentialRivera Gutierrez, R., Tama, E., Bechenati, D., Castañeda Hernandez, R., Bennett, P. K., McNally, A. W., Fansa, S., Anazco, D., Acosta, A., & Hurtado Andrade, M. D. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.07.006 · Cited by 31
Dani, S. S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., Sattar, N., Al-Kindi, S., Fonarow, G., Butler, J., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.101740 · Cited by 30
McIntyre, R. S. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2335215 · Cited by 37
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population
Buckley, A., Suliman, S., Allum, M., Mohammed, N., Lessan, N., le Roux, C. W., & Suliman, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15680 · Cited by 29
Parab, P. T., Chaudhary, P., Mukhtar, S., Moradi, A., Kodali, A., Okoye, C., Klein, D., Mohamoud, I., Olanisa, O. O., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.45487 · Cited by 52
“According to studies, tirzepatide was superior to placebo, semaglutide 1 mg/week, dulaglutide 1.5 mg/week, insulin degludec 100 U/mL, and semaglutide or insulin glargine 100 U/mL in lowering HbA1c and weight in T2D patients throughout a 26-to 52-week treatment period [36,37].”
BackgroundInfluentialBailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“Amongst agents injected QW, semaglutide ( Ozempic , 2 mg) and tirzepatide ( Mounjaro, up to 15 mg) reduced HbA1c by 2.2 % and 2.4 % respectively and reduced body weight by 6.9 kg and 11.3 kg respectively during 40 week randomised controlled trials in overweight/obese individuals with T2DM [10,11].”
InfluentialDe Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
“A target of HbA1c less than 7.0% was reached by, respectively, 68% versus 58% of people randomized to semaglutide 2.0- versus 1.0-mg QW.65 High-dose dulaglutide also dose-dependently reduced HbA1c.63,64 In AWARD-11, according to the efficacy estimand, treatment with dulaglutide 4.5-mg QW improved HbA1c by 1.87% at wee…”
BackgroundInfluentialMedical and Surgical Treatment of Obesity
Reid, T. J., & Körner, J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.03.002 · Cited by 40
Lempesis, I. G., Liu, J., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100220 · Cited by 38
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“Moreover, in a recent large cardiovascular outcomes trial (SURPASS-CVOT), numerically higher proportions of participants taking tirzepatide (15 mg weekly) reported nausea, vomiting, and diarrhea compared with those taking the selective GLP-1RA dulaglutide (1.5 mg weekly) (25).”
InfluentialValentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14979 · Cited by 28
“Treatment effects associated with tirzepatide and semaglutide therapy on risk factors, including HbA1c and body mass index (BMI), were taken from the published SURPASS-2 treatment regimen estimands, and supplemented with data from the clinical study report (Table 2).(11) Long-term HbA1c progression was based on the UK…”
BackgroundMethodResultInfluentialHu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28
Liver fat as risk factor of hepatic and cardiometabolic diseases
Demir, M., Bornstein, S. R., Mantzoros, C. S., & Perakakis, N. (2023) · Obesity Reviews · doi:10.1111/obr.13612 · Cited by 31
“Tirzepatide has been reported to be superior to semaglutide in reducing HbA1c and weight.(171) In patients with T2DM, Tirzepatide reduces significantly liver transaminases.”
BackgroundLi, H., Yu, G., Huang, Q., Yang, B., Nie, J., Liu, Y., & Tu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116150 · Cited by 38
Reframing prediabetes: A call for better risk stratification and intervention
Kim, S. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13786 · Cited by 34
“%) weight loss than semaglutide [90, 91].”
Tirzepatida: Un Avance Revolucionario en el Tratamiento de la Diabetes Mellitus Tipo 2 y la Obesidad
Chávez, M. (2023) · Revista Veritas de Difusão Cientifica. · doi:10.61616/rvdc.v4i1.39 · Cited by 35
Vazquez-Uribe, R., Hedin, K. A., Licht, T. R., Nieuwdorp, M., & Sommer, M. O. A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.021 · Cited by 28
“The emergence of tandem peptides, exempli fi ed by tirzepatide, a GIP/GLP-1 tandem peptide [91], further broadens the horizons of AMT applications for managing metabolic diseases.”
Kong, W., Deng, B., Shen, X., John, C. S., Haag, J. G., Sinha, N., Lee, D., Sun, W., Chen, S., Zhang, H., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.10.004 · Cited by 44
El-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 34
Polex-Wolf, J., Deibler, K., Hogendorf, W. F. J., Bau, S. S., Glendorf, T., Stidsen, C. E., Tornøe, C. W., Dong, T., Lundh, S. H., Pyke, C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk4908 · Cited by 35
Karhunen, V., Daghlas, I., Zuber, V., Vujkovic, M., Olsen, A. K., Knudsen, L. B., Haynes, W. G., Howson, J. M. M., & Gill, D. (2021) · Diabetologia · doi:10.1007/s00125-021-05564-7 · Cited by 28
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
Johnson, H., Huang, D., Liu, V., Ammouri, M. A., Jacobs, C., & El-Osta, A. (2025) · Journal of Medical Internet Research · doi:10.2196/69466 · Cited by 27
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis
Zhang, H., Ding, L., Liu, K., Mi, L., Zhang, A.-K., Yu, F., Yan, X.-X., Peng, F.-H., Shen, Y.-J., & Tang, M. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103067 · Cited by 37
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
“…Smit et al., 2021) and bone disorders (Gabe et al., 2022), and the incorporation of GIP activity has been suggested to contribute to the impressive glucose-lowering and body weight-reducing effects of the GLP-1 – GIP receptor co-agonist tirzepatide (Frías et al., 2021; Jastreboff et al., 2022).”
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
Kamrul-Hasan, A. B. M., Alam, M. S., Dutta, D., Sasikanth, T., Aalpona, F. T. Z., & Nagendra, L. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2164 · Cited by 27
McIntyre, R. S., Rasgon, N., Goldberg, J. F., Wong, S., Le, G. H., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Stahl, S. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925000124 · Cited by 40
“131”
Aaseth, E., Halvorsen, S., Helseth, R., & Gravning, J. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf104 · Cited by 32
Buckley, A. J., Tan, G. D., Gruszka-Goh, M. H., Scanlon, P. H., Ansari, I., & Suliman, S. G. I. (2025) · Diabetologia · doi:10.1007/s00125-025-06466-8 · Cited by 38
“Tirzepatide is a potent glucose-lowering agent and, at higher doses, provides greater HbA 1c lowering than GLP-1RAs including dulaglutide and semaglutide [20, 21].”
Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome
Nzobokela, J., Muchaili, L., Mwambungu, A., Masenga, S. K., & Kirabo, A. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1661563 · Cited by 44
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16126 · Cited by 26
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
Schneck, K. B., & Urva, S. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13099 · Cited by 43
Henriques, J., Berenbaum, F., & Mobasheri, A. (2024) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2024.100511 · Cited by 34
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Avgoustou, E., Tzivaki, I., Diamantopoulou, G., Zachariadou, T., Avramidou, D., Dalopoulos, V., & Skourtis, A. (2025) · Diagnostics · doi:10.3390/diagnostics15020169 · Cited by 39
Agarwal, A., Mustafa, R. A., Manja, V., Agoritsas, T., Macdonald, H., Li, S., Foroutan, F., Rayner, D. G., Rodríguez‐Gutiérrez, R., Åsvold, B. O., et al. (2025) · BMJ · doi:10.1136/bmj-2024-082071 · Cited by 32
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“%) were commonly reported [38, 45–47].”
InfluentialBerndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33
“This novel dual GLP-1Rs/glucosedependent insulinotropic polypeptide co-agonist has the most promising effect on weight loss and haemoglobin A1c (HbA1c) to date [16].”
BackgroundTirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
“…for improving glycemic control in patients with T2DM in eight published SURPASS trials (SURPASS 1-5, SURPASS J-mono, and SURPASS J-combo) [8-10 ,25-28 25-28] and for treating obesity in the The SURPASS trials looked at once-weekly tirzepatide doses of 5 mg, 10 mg, and 15 mg using a dose…”
BackgroundMethodResultInfluentialChichura, K. S., Elfers, C., Salameh, T. S., Kamat, V., Chepurny, O. G., McGivney, A., Milliken, B. T., Holz, G. G., Applebey, S. V., Hayes, M. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36178-1 · Cited by 27
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.